Arno Therapeutics (ARNI) Stock Analysis & Winston Score

Arno Therapeutics is a small biotechnology company focused on developing experimental drugs to treat cancer. Its lead program centers on a compound designed to block certain hormone receptors believed to drive tumor growth, with a primary focus on breast cancer patients. The company does not yet sell any approved products and is in the clinical-stage phase of drug development.

Arno generates no product revenue at this stage. It funds operations through equity raises and potentially partnerships, which is typical for early-stage biotech firms. The company operates in the United States and, given its near-zero market cap, is considered a micro-cap or shell-level entity, meaning it carries significant financial fragility. The central risk is whether its drug candidates can demonstrate safety and efficacy in clinical trials, secure regulatory approval, and attract the capital needed to survive long enough to reach commercialization.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

-158.6% YoY

YoY Growth Rate

Earnings declining

Insider Activity

15.1%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~6 months

$2M cash & investments

Short runway — potential dilution ahead through share issuance

Cash watch

Arno Therapeutics has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

—

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial